Piero Barbanti

EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world 1:56
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world
Piero Barbanti • 27 Sep 2021
New migraine targets: AMY1 & PACAP 1:24
New migraine targets: AMY1 & PACAP
Piero Barbanti • 27 Sep 2021
Predictive markers for CGRP-directed antibody treatment success in migraine 1:37
Predictive markers for CGRP-directed antibody treatment success in migraine
Piero Barbanti • 27 Sep 2021
Comparing CGRP ligand- and receptor-directed antibody treatments in migraine 4:00
Comparing CGRP ligand- and receptor-directed antibody treatments in migraine
Piero Barbanti • 27 Sep 2021
The content of VJNeurology is intended for healthcare professionals